Scholarlink

Purpose <p>Due to the clinical and prognostic implications of Graves’ Orbitopathy (GO), clinical care needs to be tailored to current recommendations, but real-life information is scarce. We aim to describe GO management in a real-life setting for health care improvement.</p> Methods <p>This is a retrospective cohort study evaluating the clinical performance of clinicians attending patients diagnosed with GO. All cases with GO from 2018 to 2021 were included in the analysis, with no exclusion criteria. We performed an evaluation of the healthcare provided to these patients, with clinical performance evaluated from diagnostic and therapeutic viewpoints. A backwards stepwise multivariate binomial logistic regression analysis was run to assess the variables associated with severity.</p> Results <p>This was a cohort of 151 cases, predominantly of women in the fifth decade of life, most of whom had hyperthyroidism. There were 50 (33.1%) cases with moderate-severe GO, but none of them with sight-threatening disease. Total annualized visits were more frequent to endocrinologists than ophthalmologists, except for moderate-severe cases. Active smoking (57 cases; 37.7%), unstable hyperthyroidism (59 cases; 39.1%), and elevated maximum TSI levels (136; 90.1%) conditioned clinical care. Altogether, the performance of an imaging technique, the use of systemic corticosteroid therapy and eyelid surgery were significantly different in those with more severe GO.</p> Conclusion <p>Clinical care provided to patients with GO is variable and influenced by several variables. Both endocrinologists and ophthalmologists must coordinate to ensure a unified patient-tailored protocol that covers all these patients’ needs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluation of the clinical management of Graves’ Orbitopathy according to severity: a real-life Analysis

  • 期刊论文

  • 发表日期：

    2025年3月22日

查看全文
  • Antonio Manuel Garrido-Hermosilla,
  • María Concepción Díaz-Ruiz,
  • Reyes Ravé-García,
  • Francisco Javier Torres-García,
  • María Leticia Lledó-de-Villar,
  • Tomás Martín-Hernández,
  • Virginia Moreira-Navarrete,
  • Francisco Javier Toyos-Sáenz-de-Miera,
  • Irene Martínez-Alberquilla,
  • Mariola Méndez-Muros

摘要

Purpose

Due to the clinical and prognostic implications of Graves’ Orbitopathy (GO), clinical care needs to be tailored to current recommendations, but real-life information is scarce. We aim to describe GO management in a real-life setting for health care improvement.

Methods

This is a retrospective cohort study evaluating the clinical performance of clinicians attending patients diagnosed with GO. All cases with GO from 2018 to 2021 were included in the analysis, with no exclusion criteria. We performed an evaluation of the healthcare provided to these patients, with clinical performance evaluated from diagnostic and therapeutic viewpoints. A backwards stepwise multivariate binomial logistic regression analysis was run to assess the variables associated with severity.

Results

This was a cohort of 151 cases, predominantly of women in the fifth decade of life, most of whom had hyperthyroidism. There were 50 (33.1%) cases with moderate-severe GO, but none of them with sight-threatening disease. Total annualized visits were more frequent to endocrinologists than ophthalmologists, except for moderate-severe cases. Active smoking (57 cases; 37.7%), unstable hyperthyroidism (59 cases; 39.1%), and elevated maximum TSI levels (136; 90.1%) conditioned clinical care. Altogether, the performance of an imaging technique, the use of systemic corticosteroid therapy and eyelid surgery were significantly different in those with more severe GO.

Conclusion

Clinical care provided to patients with GO is variable and influenced by several variables. Both endocrinologists and ophthalmologists must coordinate to ensure a unified patient-tailored protocol that covers all these patients’ needs.